Innovative Therapies for Children with Cancer
Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication : BIOMEDE
INFORM2 exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies
Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Durvalumab Monotherapy or Durvalumab in Combination with Tremelimumab in Pediatric Patients with Advanced Solid Tumors and Hematological Malignancies
A multicentre, open-label, randomised, Phase 2 study to compare the efficacy and safety of lenvatinib (LEN) in combination with ifosfamide (IFO) and etoposide (ETO) versus IFO and ETO in subjects from 5 years to <18 years (and adults) with relapsed or refractory osteosarcoma who have been treated with 1 prior chemotherapy regimen
Phase I open label, dose escalation trial to determine the MTD, safety, PK and efficacy of afatinib monotherapy in children aged 2 years to <18 years with recurrent/refractory neuroectodermal tumours, rhabdomyosarcoma and/or other solid tumours with known ErbB pathway deregulation regardless of tumour histology
A Pivotal Phase 2 Trial of Antibody Naxitamab (hu3F8) and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone/Bone Marrow
A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults with Relapsed, Recurrent, or Refractory Desmoplastic Small Round Cell Tumor
FaR-RMS: An overarching study for children and adults with Frontline and Relapsed RhabdoMyoSarcoma
